Section 89-e of the State Finance Law (SFL) established the Alzheimer’s Disease Assistance Fund, which is under the joint custody of the Commission of Taxation and Finance and the Comptroller of New York State. Section 89-e (2-b) of the SFL requires the Commissioner of Health to annually report to the Legislature, the Comptroller, and the public specified information concerning the utilization of such funds during the preceding calendar year. This report sets forth that information for calendar year 2017.

During calendar year 2017, $562,451.30 was dispersed from the Alzheimer’s Disease Assistance Fund. The funds were dispersed as follows:

**Recipient: Alzheimer’s Disease Community Assistance Program (AlzCAP): $281,546.16**

New York State funds the Coalition of Alzheimer’s Association Chapters (AlzCAP) to implement the Alzheimer’s Disease Community Assistance Program. The goal of AlzCAP is to reduce the enormous toll of Alzheimer’s disease and other dementias (AD/D) on patients and their families by promoting effective patient management, education and appropriate support for patients with AD/D, family caregivers, health care personnel, volunteers, community agencies first responders and self-help groups. Each organization provides the following services:

- Care Planning and Consultation
- Caregiver Training
- Support Groups
- 24-hour Helpline
- Community Awareness
- Increased Training for Important Constituencies

*Award Process Used: Provided to existing contractors developed through a sole source process*

**Recipient: Support for Two Behavioral Risk Factor Surveillance System (BRFSS) Modules: $60,045.66**

Funds are utilized to support questions which are part of the cognitive impairment and caregiver modules in the BRFSS. These questions allow for better data to study the incidence and impact of Alzheimer’s disease in NYS as well as the impact of the disease on families and caregivers.

*Award Process Used: Not applicable*
Recipient: Alzheimer’s Association of the Hudson Valley for a Demonstration Project to Reduce Disparities in Persons with Dementia: $169,096.21

The Alzheimer’s Association of the Hudson Valley received a contract for a two-year demonstration project focused on addressing disparities in Alzheimer’s disease. The contract began on January 1, 2016 and ended on December 31, 2017. The goal of this demonstration project was to increase AD/D screenings in primary care settings for African American and Hispanic populations, to promote earlier diagnosis and treatment of AD/D among these populations, and to connect those diagnosed with AD/D to community support, medical services and clinical trials. Long term objectives include effective disease management, continued community residence and decreased caregiver burden.

The components of the Alzheimer’s Association of the Hudson Valley’s project during the second year of the initiative included in-person training of medical professionals on identifying and addressing disparities related to Alzheimer’s disease and other dementias, provision of 70 outreach events and 34 educational programs and informational sessions to African American and Hispanic communities through faith-based organizations and training of 42 faith-based leaders.

The program has submitted an evaluation report as well as a year-end report describing the impact of the project.

Award Process Used: Competitive solicitation process

Recipient: State University at Albany School of Public Health “Public Health Live” to Produce Three Public Health Live Broadcasts: $51,763.27

Three broadcasts were developed and presented, as follows:

Determining Caregiver Needs and Wellbeing: This webcast featured a discussion of how to assess and support the caregiver’s needs to ensure that they may optimally care for their loved one living with Alzheimer’s disease.

Clinical and Ethical Indications for Cognitive Impairment Screening in Primary Care: This webcast offered three alternative perspectives to challenge current norms: (1) that knowing information about cognitive impairment or related diagnoses helps the patient and their family in multiple ways; (2) that there is a wide array of tools that are shown to be both sensitive and specific for screening, and importantly, are quick to implement; and (3) that cognitive screening and disclosure are ethically the right thing to do.

Psychiatric Manifestations of Parkinson’s Disease and its Treatment: This webcast provided information to medical and public health professionals about the psychiatric symptoms of Parkinson’s disease, the complex interaction between the organic brain disease and its treatment to enable them to recognize the psychiatric symptoms encountered in this disease, employ strategies to reduce risk factors, and develop the most appropriate treatment paradigms.

Award Process Used: Added to an existing MOU between the University at Albany School of Public Health and NYSDOH
Summary Financial Plan for the Alzheimer’s Disease Assistance Fund:

<table>
<thead>
<tr>
<th></th>
<th>SFY 2015-16</th>
<th>SFY 2016-17</th>
<th>SFY 2017-18</th>
<th>SFY 2018-19</th>
<th>SFY 2019-20</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Actuals</td>
<td>Actuals</td>
<td>As of 12/31/17</td>
<td>Projected</td>
<td>Projected</td>
</tr>
<tr>
<td>Receipts</td>
<td>$527,045</td>
<td>$538,170.80</td>
<td>$187,326.16</td>
<td>$543,000</td>
<td>$543,000</td>
</tr>
<tr>
<td>Disbursements</td>
<td>$702,515</td>
<td>$916,817.93</td>
<td>$409,607.01</td>
<td>$1,000,000</td>
<td>$1,000,000</td>
</tr>
<tr>
<td>Balance</td>
<td>$2,139,858</td>
<td>$1,761,210.93</td>
<td>$1,538,930.08</td>
<td>$768,858</td>
<td>$311,858</td>
</tr>
</tbody>
</table>